Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06413706 · ClinicalTrials.gov registry record · Phase 2
A Study Comparing Abemaciclib Plus Temozolomide to Temozolomide Monotherapy in Children and Young Adults With High-grade Glioma Following Radiotherapy
A Phase 2 study of Glioma, sponsored by Eli Lilly and Company.
- Active
- Registry status
- Phase 2
- Development phase
- 45
- Enrollment target
- 20
- Study locations
NCT06413706 is a Phase 2 study of Glioma that is active but no longer recruiting, run by Eli Lilly and Company. The registered enrollment target is 45 participants, below the 209-participant average among 87 other Glioma trials with a reported enrollment target (78% lower). The trial reports 20 study locations across 8 states.
The verdict
NCT06413706, a Phase 2 study of Glioma, is active but no longer recruiting, sponsored by Eli Lilly and Company.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 45 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to measure the benefit of adding abemaciclib to the chemotherapy, temozolomide, for newly diagnosed high-grade glioma following radiotherapy. Your participation could last approximately 11 months and possibly longer depending upon how you and your tumor respond.
Conditions Studied
Interventions
- DRUG Temozolomide
- DRUG Abemaciclib
Study Locations (20)
Other
- Queensland Government- Lady Cilento Children's Hospital - Brisbane
- Perth Children's Hospital - Nedlands
- The Children's Hospital at Westmead - Westmead
- Universitair Ziekenhuis Gent (Uz Gent) - Ghent
- Universitair Ziekenhuis Leuven - Leuven
- Universite Catholique de Louvain (UCL) - Cliniques Universitaires Saint-Luc - Woluwe-Saint-Lambert
- Copenhagen University Hospital-Rigshospitalet University Hospital - Copenhagen
- Centre Hospitalier Universitaire de Bordeaux Groupe Hospitalier Pellegrin Hopital des Enfants - Bordeaux
- Centre de Lutte Contre le Cancer (CLCC) - Centre Oscar Lambret - Lille
- Centre Leon Berard - Lyon
- Hopital La Timone - Marseille
California
- Children's Hospital of Orange County - Orange - Orange
- Lucile Packard Children's Hospital (LPCH) - Stanford University - Palo Alto
Texas
- UT Southwestern Medical Center Dallas/Childrens Medical Center - Dallas
- The University of Texas MD Anderson Cancer Center - Houston
Indiana
- Riley Hospital for Children at Indiana University Health - Indianapolis
Maryland
- The Johns Hopkins Hospital (JHH) - Johns Hopkins Childrens Center - Baltimore
Michigan
- University of Michigan Health System (UMHS) - C.S. Mott Children's Hospital - Hematology Oncology Clinic - Ann Arbor
Minnesota
- Mayo Clinic - Rochester
Rhode Island
- Rhode Island Hospital - Providence
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2024-10-25 |
| Est. Completion | 2028-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06413706
The ClinicalTrials.gov registry entry for NCT06413706 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 209-participant average among 87 other Glioma trials with a reported enrollment target (78% lower). The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Glioma appearing as the primary indexed condition, and to 2 interventions - of which Temozolomide is the first listed.
NCT06413706 reports 20 study locations spanning 8 distinct geographic areas - top geographies include Other, California, Texas.
Frequently Asked Questions
What is clinical trial NCT06413706 about?
NCT06413706 is a clinical study titled "A Study Comparing Abemaciclib Plus Temozolomide to Temozolomide Monotherapy in Children and Young Adults With High-grade Glioma Following Radiotherapy". The purpose of this study is to measure the benefit of adding abemaciclib to the chemotherapy, temozolomide, for newly diagnosed high-grade glioma following radiotherapy. Your participation could last approximately 11 months and possibly longer depending upon how you and your tumor respond.
What is the current status of trial NCT06413706?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 45 participants. The study started on 2024-10-25. Estimated completion is 2028-02.
What conditions does trial NCT06413706 study?
This clinical trial studies the following conditions: Glioma.
What interventions are being tested in trial NCT06413706?
The interventions under investigation include: Temozolomide (DRUG), Abemaciclib (DRUG).
Who is sponsoring clinical trial NCT06413706?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06413706 being conducted?
This trial has 20 study locations across California, Indiana, Maryland, Michigan, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glioma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
All-Trans Retinoic Acid (ATRA) Plus PD-1 Inhibition in Recurrent IDH-Mutant Glioma
RECRUITING · Phase 2
-
Pembrolizumab, Olaparib, and Temozolomide for People With Glioma
RECRUITING · Phase 2
-
Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII
RECRUITING · Phase 2
-
Methimazole in Patients With Progressive Glioblastoma
RECRUITING · Phase 2
-
Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA
RECRUITING · Phase 2
-
A Study Utilizing Escitalopram in Glioma Patients
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.